NCT04617600

Brief Summary

The aim of the study is to assess the effect of TheraCal PT pulpotomy versus MTA pulpotomy on the survival rate of cariously exposed vital primary molars.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2022

Shorter than P25 for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 22, 2020

Completed
14 days until next milestone

First Posted

Study publicly available on registry

November 5, 2020

Completed
1.3 years until next milestone

Study Start

First participant enrolled

March 1, 2022

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2022

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2022

Completed
Last Updated

March 4, 2022

Status Verified

March 1, 2022

Enrollment Period

3 months

First QC Date

October 22, 2020

Last Update Submit

March 2, 2022

Conditions

Outcome Measures

Primary Outcomes (4)

  • Survival rate (Absence of spontaneous pain)

    Binary outcome measured with direct questioning to the patient

    "3 months"

  • Survival rate (Absence of spontaneous pain)

    Binary outcome measured with direct questioning to the patient

    "6 months"

  • Survival rate (Absence of swelling)

    Binary outcome measured visually by intraoral/extraoral examination

    "3 months"

  • Survival rate (Absence of swelling)

    Binary outcome measured visually by intraoral/extraoral examination

    "6 months"

Secondary Outcomes (2)

  • Absence of periapical radiolucency or absence of internal/external root resorption

    "6 months"

  • Time lapse till final restoration performed.

    "During procedure".

Study Arms (2)

Mineral trioxide aggregate (MTA)

ACTIVE COMPARATOR

Survival rate of cariously exposed vital primary molars using MTA+ Curamed (UI, Kwiatkowskiego 1, 37-450 Staleya Wola, Polka)

Drug: MTA

TheraCal PT

EXPERIMENTAL

Survival rate of cariously exposed vital primary molars using TheraCal PT (BISCO Dental Products, Schamberg IL, U.S.A.)

Drug: TheraCal PT

Interventions

MTADRUG

Survival rate using MTA in cariously exposed vital primary molars

Also known as: Mineral trioxide aggregate
Mineral trioxide aggregate (MTA)

Survival rate using TheraCal PT in cariously exposed vital primary molars

Also known as: TheraCal PT®
TheraCal PT

Eligibility Criteria

Age4 Years - 7 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Aged 4 to 7 years , in good general health and mentally free.
  • The parents provided written informed consent.
  • Cariously exposed primary molars with reversible pulpitis.
  • Teeth should be vital.
  • Restorable teeth.
  • Hemostasis achieved after complete pulpotomy

You may not qualify if:

  • With systemic disease.
  • Physical or mental disability.
  • Unable to attend follow-up visits.
  • Refusal of participation.
  • Previously accessed teeth.
  • History of spontaneous or prolonged pain.
  • Swelling, tenderness to percussion or palpation, or pathological mobility.
  • Pre-operative radiographic pathology such as resorption(internal or external),per-radicular or furcation radiolucency.
  • Haemorrhage control is unachievable after pulpotomy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Pemetrexedmineral trioxide aggregate

Intervention Hierarchy (Ancestors)

GuanineHypoxanthinesPurinonesPurinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsGlutamatesAmino Acids, AcidicAmino AcidsAmino Acids, Peptides, and ProteinsAmino Acids, Dicarboxylic

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

October 22, 2020

First Posted

November 5, 2020

Study Start

March 1, 2022

Primary Completion

June 1, 2022

Study Completion

November 1, 2022

Last Updated

March 4, 2022

Record last verified: 2022-03

Data Sharing

IPD Sharing
Will not share